MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80 (B7-1)/PD-L1 PROTEIN/PROTEIN INTERACTIONS

The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.

Saved in:
Bibliographic Details
Main Authors SANGHVI, Nishith, MILLER, Michael Matthew, ZHU, Juliang, SUN, Li-Qiang, ALLEN, Martin Patrick, YEUNG, Kap-Sun, GILLMAN, Kevin W, LANGLEY, David R, TENNEY, Daniel J, BOWSHER, Michael S, GILLIS, Eric P, GRANT-YOUNG, Katharine A, MAPELLI, Claudio, MULL, Eric, ZHAO, Qian, SCOLA, Paul Michael, CORNELIUS, Lyndon, A., M, POIRIER, Maude A
Format Patent
LanguageEnglish
French
German
Published 19.07.2017
Subjects
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES
MEASURING
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PHYSICS
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
TESTING
Online AccessGet full text

Cover

More Information
Summary:The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
Bibliography:Application Number: EP20140776949